The results from liver cancer patients showed that those with GPNCA expression (FPKM value) > 0.295 were of high-risk and had poor survival (HR = 1.890, 95% CI, 1.278–2.795, P = 0.0012), (Fig. 3B and Supplemental Fig. S1B); whilst renal clear cell cancer patients with GPNCA expression (FPKM value) > 0.421 were of high-risk resulting in poor OS (AUC value > 0.5, HR = 2.166, 95% CI, 1.269–3.698, P = 0.0002)(Fig. 3C and Supplemental Fig. S1C). The gene discussed is GSK3B-DT; the disease is liver cancer.